Answers are grounded in this paper and cite their sources.
OBJECTIVE: To evaluate the impact on mortality of standard Schwarz measles immunisation before 9 months of age. DESIGN: Children vaccinated in 1980-3 at 4-5, 6-8, and 9-11 months of age were followed to migration, death, or the age of 5 years. SETTING: One urban district and nine villages in two rural areas of Guinea-Bissau. SUBJECT: 307 children vaccinated at 4-8 months and 256 at 9-11 months. MAIN OUTCOME MEASURES: Mortality from 9 months to 5 years of age for children immunised at 4-5, 6-8, and 9-11 months. RESULTS: Mortality was significantly lower in children vaccinated at 6-8 months than at 9-11 months (mortality ratio = 0.63, (95% confidence interval 0.41 to 0.97), p = 0.047). As vaccination was provided in semiannual or annual campaigns it is unlikely that age at vaccination reflected a selection bias. The trend was the same in all three study areas. Improved survival after early immunisation was not related to better protection against measles infection. With a Cox multivariate regression model to adjust for age, sex, season at risk, season at birth, measles infection, and region, children vaccinated at 4-8 months had a mortality ratio of 0.61 (0.40 to 0.92, p = 0.020) compared with children vaccinated at 9-11 months. Reimmunised children tended to have lower mortality than children who received only one vaccine (0.59 (0.28 to 1.27, p = 0.176)). CONCLUSION: Standard measles vaccination before 9 months is not associated with higher childhood mortality than is the currently recommended strategy of immunising from 9 months, and it may reduce mortality. This has implications for measles immunisation strategy in developing countries.
No takes yet. Share an insight, caveat, or question.
Aaby et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: